Oncolytics Biotech Inc.
ONCY
$0.89
$0.011.40%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 101.72% | -14.78% | -8.17% | -9.91% | -41.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.45% | -28.75% | -24.65% | -7.34% | -11.89% |
| Operating Income | -38.45% | 28.75% | 24.65% | 7.34% | 11.89% |
| Income Before Tax | -52.23% | 16.03% | 8.88% | -98.91% | 5.49% |
| Income Tax Expenses | -2,179.55% | -11.53% | -- | -48.10% | 69.23% |
| Earnings from Continuing Operations | -49.43% | 15.97% | 8.88% | -97.31% | 5.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.43% | 15.97% | 8.88% | -97.31% | 5.44% |
| EBIT | -38.45% | 28.75% | 24.65% | 7.34% | 11.89% |
| EBITDA | -38.71% | 28.81% | 24.69% | 7.25% | 12.05% |
| EPS Basic | -13.66% | 29.70% | 18.97% | -87.79% | 14.34% |
| Normalized Basic EPS | -15.70% | 29.77% | 19.06% | -89.30% | 14.35% |
| EPS Diluted | -13.66% | 29.70% | 18.97% | -87.79% | 14.34% |
| Normalized Diluted EPS | -15.70% | 29.77% | 19.06% | -89.30% | 14.35% |
| Average Basic Shares Outstanding | 31.55% | 19.59% | 12.48% | 5.11% | 10.33% |
| Average Diluted Shares Outstanding | 31.55% | 19.59% | 12.48% | 5.11% | 10.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |